Invesco
IVZ
$28.20
-2.08%
Invesco is a global asset manager providing investment management services to retail (72% of managed assets) and institutional (28%) clients, with $2.562 trillion in assets under management as of August 2026 spread across equity (62%), fixed income (19%), money market (11%), alternatives (5%), and balanced (3%) strategies, with passive products accounting for close to half of total AUM. The firm is one of the ten largest nonproprietary fund complexes in the US retail market and derives 31% of AUM from outside North America, giving it a distinctly global footprint among mid-tier asset managers. The current investor narrative centers on a sharp swing back to profitability in 2026 following a Q4 2025 goodwill and intangible impairment that produced a $1.06 billion quarterly loss, alongside a 20.5% year-over-year revenue acceleration in Q2 2026 that has revived debate over whether Invesco can convert market-driven AUM appreciation into durable organic growth. Sentiment has been further shaped by the stock's 23.7% one-year gain outpacing the S&P 500's 15.5%, even as a recent one-month pullback of 6.3% has raised questions about whether the recovery trade is overextended.…
IVZ
Invesco
$28.20
Related headlines
Investment Opinion: Should I buy IVZ Today?
The synthesized recommendation is Buy, with a thesis that Invesco offers an asymmetric risk/reward at 8.7x forward earnings and 0.97x book value, supported by a 'buy' consensus from 14 analysts and an average target of $34.64, roughly 23% above the current $28.20. The core reasoning is that the market is pricing the stock for a failed recovery, while the Q2 2026 results show revenue growth of 20.5% and operating income of $364 million, suggesting the recovery is real.
The supporting evidence is strong: forward EPS of $4.25 implies an 8.7x multiple, well below the market average; Q2 2026 revenue of $1.826 billion grew 20.5% year-over-year; trailing free cash flow of $1.965 billion equals about 16.6% of the $11.85 billion market cap; and the 4.9% dividend yield provides income while waiting for the re-rating. The price-to-sales ratio of 1.86 and price-to-book of 0.97 are modest for an asset manager with $2.562 trillion in AUM, and the analyst low target of $30.00 is above the current price, indicating that even the bearish sell-side view sees upside.
The biggest risks that could invalidate the thesis are a renewed market downturn that reduces AUM and triggers another impairment, continued organic outflows that undermine the growth narrative, and the high beta of 1.63 that amplifies drawdowns. The rating would upgrade to a stronger Buy if organic inflows turn positive for two consecutive quarters, and it would downgrade to Hold if the stock breaks below the $26 support level or if forward EPS estimates fall below $4.00. On valuation, the stock is undervalued relative to its own forward earnings power and slightly below book value, though it is fairly valued relative to the cautious analyst consensus that already embeds a recovery.
Sign up to view all
IVZ 12-Month Price Forecast
The forward-looking view is bullish but with medium confidence, because the valuation and analyst targets are compelling while the organic growth story remains unproven. At 8.7x forward EPS and 0.97x book, the stock already discounts a failed recovery, so the risk/reward is skewed to the upside if Q2 2026's 20.5% revenue growth proves sustainable. The 4.9% dividend yield and $1.965 billion free cash flow provide a margin of safety, but the 1.63 beta means the stock will not be spared in a market downturn. I would upgrade to high confidence if Invesco reports positive organic inflows for two consecutive quarters, and I would downgrade to neutral if the stock breaks below $26 or if forward EPS estimates fall below $4.00.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Invesco's 12-month outlook, with a consensus price target around $34.64 and implied upside of +22.9% versus the current price.
Average Target
$34.64
0 analysts
Implied Upside
+22.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$30 - $41
Analyst target range
Bulls vs Bears: IVZ Investment Factors
The bull case rests on a genuine earnings recovery: Q2 2026 revenue grew 20.5% year-over-year, forward EPS of $4.25 supports an 8.7x multiple, and analysts see 23% upside to a $34.64 average target. The bear case is equally grounded: the Q4 2025 impairment showed how fragile reported earnings are, organic growth is unproven, and the stock's 1.63 beta and 22.7% max drawdown make it a high-risk holding in any market downturn. On balance, the evidence currently favors the bulls, because the forward earnings multiple, free cash flow yield of roughly 16.6%, and analyst consensus all point to a stock that is priced for skepticism rather than optimism. The single most important tension is whether Invesco can convert market-driven AUM appreciation into durable organic inflows; if it can, the 8.7x forward PE re-rates toward the mid-teens, but if flows remain weak, the recovery trade likely stalls.
Bullish
- Revenue growth accelerating sharply: Q2 2026 revenue of $1.826 billion grew 20.5% year-over-year, a marked acceleration from the roughly 8% growth implied by Q1 2026's $1.745 billion versus Q1 2025's $1.529 billion. This top-line momentum, driven by market appreciation and a rebound from the Q4 2025 impairment, suggests operating leverage is returning to the model.
- Forward earnings multiple is very low: At $28.20, IVZ trades at just 8.7x forward EPS of $4.25, versus a trailing PE that is negative due to the one-time Q4 2025 goodwill impairment. The forward multiple implies the market is pricing in significant skepticism about the durability of the earnings recovery, leaving room for re-rating if results hold.
- Analyst targets imply meaningful upside: The 14-analyst consensus is 'buy' with an average target of $34.64, roughly 23% above the current price. Even the low target of $30.00 sits about 6% above the current price, indicating that sell-side analysts see limited downside from here.
- Strong free cash flow generation: IVZ generated $1.965 billion in trailing-twelve-month free cash flow, which is roughly 16.6% of its $11.85 billion market cap. This cash generation supports the 4.9% dividend yield and provides flexibility to reduce the 0.80 debt-to-equity ratio.
Bearish
- Organic growth remains unproven: The 20.5% revenue growth in Q2 2026 was largely market-driven, with passive products accounting for close to half of the $2.562 trillion AUM. Invesco has not demonstrated durable organic inflows, and the recent 6.3% one-month pullback suggests investors are questioning whether the recovery trade is overextended.
- Impairment reveals earnings fragility: The Q4 2025 goodwill and intangible impairment produced a $1.06 billion quarterly loss and a -$2.63 EPS, wiping out roughly a full year of prior profits. This highlights how sensitive the balance sheet is to AUM declines and how quickly reported earnings can swing from positive to deeply negative.
- High beta amplifies market drawdowns: IVZ has a beta of 1.63, meaning it is roughly 63% more volatile than the S&P 500. In a market correction, the stock would likely fall disproportionately, and its 22.7% max drawdown over the past 180 days illustrates the magnitude of potential losses.
- Recent relative underperformance: Over the past three months, IVZ has fallen 4.8% while the S&P 500 gained 2.7%, a relative underperformance of 7.5 percentage points. The one-month relative strength of -7.5% versus the S&P 500's +1.2% suggests near-term momentum has turned negative.
IVZ Technical Analysis
Beta
1.63
1.63x market volatility
Max Drawdown
-22.7%
Largest decline past year
52-Week Range
$21-$34
Price range past year
Annual Return
+23.7%
Cumulative gain past year
| Period | IVZ Return | S&P 500 |
|---|---|---|
| 1m | -6.3% | +0.2% |
| 3m | -4.8% | +2.9% |
| 6m | +13.7% | +8.4% |
| 1y | +23.7% | +14.9% |
| ytd | +4.7% | +11.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IVZ Fundamental Analysis
Quarterly Revenue
$1.8B
2026-06
Revenue YoY Growth
+20.5%
YoY Comparison
Gross Margin
99.6%
Latest Quarter
Free Cash Flow
$2.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IVZ Overvalued?
PE
-16.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 6x~15x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-50.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on earnings quality and balance-sheet sensitivity. The Q4 2025 goodwill and intangible impairment produced a $1.06 billion quarterly loss and a -$2.63 EPS, demonstrating that a single adverse AUM environment can wipe out roughly a full year of profits. The debt-to-equity ratio of 0.80 is moderate but not trivial for an asset manager, and the 4.9% dividend yield has a negative payout ratio of -2.07 on a GAAP basis, meaning the dividend is currently funded by cash flow rather than accounting earnings. Free cash flow of $1.965 billion provides a cushion, but any deterioration in AUM would pressure both fee revenue and the dividend's perceived safety.
Market and competitive risks are amplified by the stock's high beta of 1.63 and its passive-heavy AUM mix. With passive products accounting for close to half of the $2.562 trillion in AUM, Invesco is structurally exposed to fee compression and to the growing dominance of low-cost index providers, which limits pricing power. The stock's 22.7% max drawdown over the past 180 days and its 7.5 percentage point underperformance versus the S&P 500 over the past three months show how quickly sentiment can reverse. Recent news that BlackRock beat Q3 earnings yet still underperformed the S&P 500 year-to-date underscores that even strong results may not be rewarded in this sector, a rotation risk that applies directly to IVZ.
In a worst-case scenario, a market correction of 15-20% would reduce AUM, compress fee revenue, and likely push the stock toward its 52-week low of $20.67, which is about 27% below the current $28.20. If organic outflows accelerate at the same time, the forward EPS estimate of $4.25 could be cut, and the stock could trade below the analyst low target of $30.00, which is already above the current price and therefore offers little downside protection. A realistic adverse outcome is a decline of 20-27% to the $20.67-$22.50 range, with the 22.7% max drawdown as a historical guide. The key trigger would be a combination of equity market weakness and a high-profile fund outflow that undermines confidence in the recovery narrative.
FAQ
The most severe risk is earnings fragility: the Q4 2025 impairment produced a $1.06 billion loss and -$2.63 EPS, showing that a single adverse AUM environment can wipe out a year of profits. Second is market sensitivity, with a beta of 1.63 and a 22.7% max drawdown over the past 180 days, meaning a market correction would hit IVZ disproportionately. Third is competitive fee pressure, as passive products account for close to half of the $2.562 trillion AUM, limiting pricing power against low-cost index providers. Fourth is dividend risk, since the 4.9% yield has a negative payout ratio of -2.07 on a GAAP basis and depends on continued free cash flow of $1.965 billion.
The 12-month forecast has three scenarios: a 30% probability bull case targeting $36-$41, a 50% probability base case targeting $32-$35, and a 20% probability bear case targeting $20.67-$26.00. The base case is most likely and assumes forward EPS of $4.25 is achieved, equity markets deliver mid-single-digit returns, and organic flows remain slightly negative but stable, pushing the stock toward the $34.64 analyst average target. The bull case requires positive organic inflows and a re-rating toward the $41.00 high target, while the bear case assumes a 15-20% market correction that compresses AUM and retests the 52-week low.
IVZ appears undervalued on forward earnings: the 8.7x forward PE is low in absolute terms and well below the market average, while the 0.97x price-to-book means the stock trades slightly below its accounting net asset value. The trailing PE of -16.3 and negative net margin of -4.4% are artifacts of the Q4 2025 goodwill impairment and do not reflect the forward earnings power of $4.25 per share. The market is therefore pricing in skepticism about the durability of the recovery, and a re-rating toward the mid-teens multiple would imply significant upside. Relative to its own history and to the analyst consensus, the stock is fairly valued to undervalued, not overvalued.
From a risk/reward perspective, IVZ looks attractive: at $28.20 it trades at 8.7x forward EPS of $4.25 and 0.97x book value, with a 23% upside to the $34.64 analyst average target and even the low target of $30.00 above the current price. The biggest downside risk is a market correction that, given the 1.63 beta, could push the stock toward its 52-week low of $20.67, roughly 27% below the current price. The stock is therefore a good buy for income-oriented investors who can tolerate volatility and who believe the Q2 2026 revenue growth of 20.5% is sustainable, but it is less suitable for investors who cannot withstand a 20-27% drawdown.
IVZ is better suited for a medium-to-long-term holding period of at least 12-18 months, because the recovery thesis depends on several quarters of earnings delivery and on the market gradually re-rating the 8.7x forward multiple. The 4.9% dividend yield rewards patience, and the $1.965 billion free cash flow supports the payout while waiting. Short-term trading is less appropriate given the 1.63 beta, the 22.7% max drawdown, and the 7.5 percentage point underperformance versus the S&P 500 over the past three months, which make near-term price direction difficult to predict. A minimum holding period of one year aligns with the base-case target of $32-$35.